Manzarbeitia-Arroba Begoña, Hodolic Marina, Pichler Robert, Osipova Olga, Soriano-Castrejón Ángel Maria, García-Vicente Ana María
Nuclear Medicine Department, University Hospital of Toledo, 45007 Toledo, Spain.
Nuclear Medicine Department, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic.
Cancers (Basel). 2023 Dec 30;16(1):195. doi: 10.3390/cancers16010195.
The follow-up of glioma patients after therapeutic intervention remains a challenging topic, as therapy-related changes can emulate true progression in contrast-enhanced magnetic resonance imaging. F-fluoroethyl-tyrosine (F-FET) is a radiopharmaceutical that accumulates in glioma cells due to an increased expression of L-amino acid transporters and, contrary to gadolinium, does not depend on blood-brain barrier disruption to reach tumoral cells. It has demonstrated a high diagnostic value in the differentiation of tumoral viability and pseudoprogression or any other therapy-related changes, especially when combining traditional visual analysis with modern radiomics. In this review, we aim to cover the potential role of 18F-FET positron emission tomography in everyday clinical practice when applied to the follow-up of patients after the first therapeutical intervention, early response evaluation, and the differential diagnosis between therapy-related changes and progression.
对胶质瘤患者进行治疗干预后的随访仍然是一个具有挑战性的课题，因为在对比增强磁共振成像中，与治疗相关的变化可能会模拟真正的病情进展。F-氟乙基酪氨酸（F-FET）是一种放射性药物，由于L-氨基酸转运蛋白表达增加，它会在胶质瘤细胞中积聚，并且与钆不同，它不需要血脑屏障破坏就能到达肿瘤细胞。在区分肿瘤存活、假性进展或任何其他与治疗相关的变化方面，它已显示出很高的诊断价值，尤其是将传统视觉分析与现代放射组学相结合时。在本综述中，我们旨在探讨18F-FET正电子发射断层扫描在日常临床实践中的潜在作用，当应用于首次治疗干预后患者的随访、早期反应评估以及区分与治疗相关的变化和病情进展时。
